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ABSTRACT
Susceptibility to erythromycin and clindamycin
was determined in 860 consecutive clinical iso-
lates of b-haemolytic streptococci belonging to
groups A (GAS, n = 134), B (GBS, n = 689), C
(GCS, n = 19) and G (GGS, n = 18). Erythromycin
resistance was 26.1% in GAS, 15.7% in GBS, 5.3%
in GCS and 33.3% in GGS. The highest rate of
clindamycin resistance (33.3%) was in GGS,
followed by GBS (15.8%), GCS (15.8%) and GAS
(5.2%). The M phenotype was predominant in
GAS (80%), the constitutive MLSB phenotype was
predominant in GBS (75%), and all GGS isolates
showed the inducible MLSB phenotype. The
uncommon erythromycin-susceptible and clinda-
mycin-resistant phenotype was found in four GBS
and two GCS isolates.
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An increase in erythromycin and clindamycin
resistance among b-haemolytic streptococci has
been observed worldwide, with different preva-
lences reported among countries and even within
the same region [1,2]. Resistance to these antibi-
otics in streptococci can be ascribed mostly to
active efflux or ribosomal target site modification
[3]. Active drug efflux is mediated by the mem-
brane-associated pump encoded by the mef genes,
and confers resistance only to 14- and 15-mem-
bered macrolides (M phenotype) [3]. Ribosomal
modifications, also called MLSB resistance, result
from the action of methylases encoded by the erm
genes [3], and can be either constitutive (cMLSB)
or inducible (iMLSB) [3,4]. The aim of the present
study was to investigate the mechanism(s) of
resistance to erythromycin and clindamycin
among clinical isolates of b-haemolytic strepto-
cocci from Seville, Spain.
In total, 860 consecutive isolates of b-haemolytic
streptococci were collected from the Microbiology
Laboratory of the University Hospital Virgen del
Rocı´o (Seville, Spain), comprising 134 group A
streptococci (GAS), 689 group B streptococci
(GBS), 19 group C streptococci (GCS) and 18
group G streptococci (GGS). Of these, 645 GBS
were collected from vaginal exudates (n = 575) of
pregnant women and from urine samples (n = 70)
during the first 6 months of 2004. The remaining
44 isolates were isolated consecutively from blood
cultures (n = 39) and cerebrospinal fluid samples
(n = 5) between 2001 and 2004. The GAS, GCS and
GGS were recovered during 2003 from pharyngeal
exudates (GAS, n = 72; GCS, n = 12; GGS, n = 1),
ear specimens (GAS, n = 13; GCS, n = 2), wounds
(GAS, n = 28; GCS, n = 1; GGS, n = 15), blood and
sterile sites (GAS, n = 7; GCS, n = 3; GGS, n = 1)
and other sources (GAS, n = 14; GCS, n = 1; GGS,
n = 1). One isolate from each patient was stored at
)70C for further studies.
Resistance phenotypes were determined by the
double disk-diffusion test as described previously
[1]. Erythromycin and clindamycin susceptibility
was determined by the microdilution method,
using Mueller–Hinton broth supplemented with
lysed horse blood 5% v ⁄v, incubated in an aerobic
atmosphere as recommended by the CLSI [5]. CLSI
interpretation criteria were used for all agents.
Real-time PCR was performed using primers
specific for the mef(A) ⁄ (E), erm(A) subclass
erm(TR) and erm(B) genes, as described by Weber
et al. [6], and for the lin(B) genes as described by
Bozdogan et al. [7], using FastStart DNA Master-
Plus SYBR Green I (Roche, Mannheim, Germany).
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Positive and negative controls from the laboratory
collection were used in all PCRs. DNA amplicons
were digested with BamHI to discriminate
between mef(A) and mef(E) [8].
The prevalence of erythromycin resistance was
26.1% in GAS, 15.7% in GBS, 5.3% in GCS and
33.3% in GGS. The highest rate of clindamycin
resistance (33.3%) was found in GGS, followed by
GBS (15.8%), GCS (15.8%) and GAS (5.2%). In
GAS, GCS and GGS, the prevalence of erythro-
mycin resistance was similar in isolates from
wounds, blood, sterile sites and pharyngeal exu-
dates. Resistance to erythromycin and clindamy-
cin was similar in GBS from vaginal samples
(15.8% and 16%, respectively) and from blood
cultures (13.6% and 13.6%, respectively).
The M phenotype was most prevalent (80%)
among GAS (Table 1), and this prevalence was
higher in the present study than in the neighbour-
ing countries of France [6] and Italy [9]. All of the
GAS with the M phenotype carried the subclass
mef(A) gene, as reported originally by Clancy et al.
[10]. In contrast, the subclass mef(E) gene has been
found in GAS in France [11]. The iMLSB pheno-
type in GAS has been associated with the erm(A)
subclass erm(TR) gene in previous studies [1,12],
but the single GAS isolate in the present study
with the iMLSB phenotype carried the erm(B) gene
and expressed high-level erythromycin resistance.
In theGBSgroup, the cMLSB phenotypewaspre-
dominant (75% of isolates). Resistance was associ-
ated with erm(B) in most isolates, but was
associated with erm(A) subclass erm(TR), either
alone or in combinationwith erm(B), in 19.7% (16 of
81) of GBS with the cMLSB phenotype (Table 1).
Previous studies have reported erm(A) subclass
erm(TR) in GBS with constitutive resistance, prob-
ably because of a mutation that results in constit-
utive expression of the erm(A) subclass erm(TR)
gene [1,4]. The second most common resistance
phenotype among GBS was the iMLSB phenotype,
associated with the erm(A) subclass erm(TR) gene,
either alone or in combination with other genes
(Table 1). Finally, the M phenotype was present in
only three isolates that harboured the subclass
mef(E) gene. The subclass mef(A) gene is rarely
reported amongGBS [13]. The present study found
higher rates of erm(A) subclass erm(TR) + erm(B),
and of erm(A) subclass erm(TR) + mef(A) than have
been reported previously [1,14].
Four additional GBS and two GCS blood
isolates were found to be susceptible to erythro- T
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mycin and resistant to clindamycin, with eryth-
romycin MICs of 0.125 and 0.06 mg ⁄L, and
clindamycin MICs of 64 and 4 mg ⁄L, for the GBS
and GCS, respectively. This resistance phenotype
has been associated previously with a lincosa-
mide-inactivating nucleotidyltransferase encoded
by the linB gene in Enterococcus faecium [7]; how-
ever, the linB gene was not detected in any of these
six isolates. Although this resistance phenotype
has been reported in other streptococci [10,15–17],
it has not been described previously in GCS
[18,19]. These six isolates were negative according
to PCR for all the resistance genes investigated.
Overall, the present study revealed that the
prevalence of macrolide resistance and the distri-
bution of resistance phenotypes differed among
b-haemolytic streptococci. The iMLSB phenotype
accounted for 19.9% of the erythromycin-resistant
streptococci (Table 1); therefore, it is important to
perform double disk-diffusion tests according to
CLSI recommendations [5] to verify clindamycin
resistance in a routine clinical diagnostic labora-
tory. The emergence of the erythromycin-suscep-
tible and clindamycin-resistant phenotype among
streptococci indicates the need for further studies
to elucidate the biochemical and genetic basis of
this resistance mechanism.
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